

**Session Title:** #78: Neurologic Complications of Cancer Therapies

**Session Type:** Education Session

**Date:** Friday, June 4

**Location:** S100b

**Time:** 1:00 PM - 2:15 PM

- Peripheral Neuropathies

*David Schiff, MD*

- CNS complications (including effects of targeted therapies)

*Patrick Y. Wen, MD*

- Radiation and chemotherapy effects on cognition (including chemo brain)

*Michelle Monje, MD, PhD*

---

**Session Title:** #53: Geriatric Issues in Neuro-oncology

**Session Type:** Education Session

**Date:** Friday, June 4

**Location:** S100b

**Time:** 2:45 PM - 4:00 PM

- Geriatric Neuro-oncology: Overview with Lessons from Primary CNS Lymphoma

*Lauren E. Abrey, MD*

- Radiotherapy of Brain Tumors in the Elderly: Issues and Controversies

*Glenn S Bauman, MD*

- Glioblastoma in the Elderly

*Alba Ariela Brandes, MD*

**Session Title:** #61: Improving Clinical Trial Outcome in Neuro-oncology

**Session Type:** Education Session

**Date:** Friday, June 4

**Location:** S100b

**Time:** 4:30 PM - 5:45 PM

- Optimizing the role of Genotyping for patient care and trial design  
*Ingo K. Mellinghoff, MD*
- Novel Trial Design in Neuro-Oncology  
*Donald A. Berry, PhD*
- Optimal Trial Endpoints in the Era of Anti-Angiogenic Therapies: Lessons learned from Bevacizumab  
*Timothy Cloughesy, MD*

**Session Title:** #174: Central Nervous System Tumors

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S103

**Time:** 8:00 AM - 12:00 PM

- Central Nervous System Tumors  
*David Peereboom, MD*
- Central Nervous System Tumors  
*Deric M. Park, MD*
- 1 #2009-ANG1005: Results of a phase I study in patients with recurrent malignant glioma.  
*Jan Drappatz*
- 2 #2010-Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study.  
*Karen Fink*
- 3 #2011-Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).  
*David Schiff, MD*
- 4 #2012-Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma.  
*Jaishri O'Neill Blakeley*
- Discussion

5 #2013-Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS consortium study.

*Stuart Grossman, MD*

6 #2014-Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).

*Rose Lai*

7 #2015-The efficacy of interferon- $\beta$ ; and temozolomide combination therapy for newly diagnosed primary glioblastoma: Multicenter study.

*Kazuya Motomura*

8 #2016-Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D.

*Jann Nagina Sarkaria*

9 #2017-Testosterone levels in men undergoing treatment for malignant gliomas.

*Matthias Holdhoff*

- Discussion

*Martin Kelly Nicholas, MD, PhD*

10 #2018-NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

*Evanthia Galanis, MD*

11 #2019-Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas.

*Shirley S. Ong*

12 #2020-Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy.

*Michael L. Gruber*

13 #2021-Radiographic patterns of relapse in glioblastoma.

*Marc C. Chamberlain, MD*

14 #2022-Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenic drugs?

*Enrico Franceschi, MD*

15 #2023-Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).

*James J. Vredenburgh*

16 #2024-Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab.

*Jing Wu*

17 #2025-Deletion of NFKBIA in malignant gliomas.

*Markus Bredel*

18 #2026-Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme.

*Christel Heidemans-Hazelaar*

19 #2027-Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study.

*Philippe Metellus*

20 #2028-CD133 expression in glioblastoma recurring after radiation therapy.

*Tonia Cenci*

21 #2029-Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendroglial tumors: A translational study of the EORTC Brain Tumor Group.

*Matthias Preusser*

22 #2030-Stereotactic radiosurgery: A new paradigm for melanoma and renal cell carcinoma spine metastases.

*Anu Thiagaragan, MD*

23 #2031-Chemotherapy (CT) alone for epidural spinal cord compression (ESCC) from germ cell tumors (GCT).

*Christian Grommes*

24 #2032-Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST).

*Lakshmi Nayak*

- Discussion

*Eric L. Chang, MD*

---

**Session Title:** #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

*Daniel D. Von Hoff, MD*

---

**Session Title:** #241: Central Nervous System Tumors

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 12:00 PM - 1:00 PM

- Central Nervous System Tumors

*David Peereboom, MD*

- Central Nervous System Tumors

*Deric M. Park, MD*

1 #2009-ANG1005: Results of a phase I study in patients with recurrent malignant glioma.

*Jan Drappatz*

2 #2010-Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study.

*Karen Fink*

3 #2011-Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).

*David Schiff, MD*

4 #2012-Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma.

*Jaishri O'Neill Blakeley*

- Discussion

*John L. Villano, MD, PhD*

5 #2013-Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS consortium study.

*Stuart Grossman, MD*

6 #2014-Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).

*Rose Lai*

7 #2015-The efficacy of interferon- $\beta$ ; and temozolomide combination therapy for newly diagnosed primary glioblastoma: Multicenter study.

*Kazuya Motomura*

8 #2016-Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D.

*Jann Nagina Sarkaria*

9 #2017-Testosterone levels in men undergoing treatment for malignant gliomas.

*Matthias Holdhoff*

- Discussion

*Martin Kelly Nicholas, MD, PhD*

10 #2018-NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

*Evanthia Galanis, MD*

11 #2019-Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas.

*Shirley S. Ong*

12 #2020-Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy.

*Michael L. Gruber*

13 #2021-Radiographic patterns of relapse in glioblastoma.

*Marc C. Chamberlain, MD*

14 #2022-Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs?

*Enrico Franceschi, MD*

15 #2023-Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).

*James J. Vredenburgh*

16 #2024-Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab.

*Jing Wu*

17 #2025-Deletion of NFKBIA in malignant gliomas.

*Markus Bredel*

18 #2026-Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme.

*Christel Heidemans-Hazelaar*

19 #2027-Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study.

*Philippe Metellus*

20 #2028-CD133 expression in glioblastoma recurring after radiation therapy.

*Tonia Cenci*

21 #2029-Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendroglial tumors: A translational study of the EORTC Brain Tumor Group.

*Matthias Preusser*

22 #2030-Stereotactic radiosurgery: A new paradigm for melanoma and renal cell carcinoma spine metastases.

*Anu Thiagaragan, MD*

23 #2031-Chemotherapy (CT) alone for epidural spinal cord compression (ESCC) from germ cell tumors (GCT).

*Christian Grommes*

24 #2032-Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST).

*Lakshmi Nayak*

- Discussion

*Eric L. Chang, MD*

---

**Session Title:** #147: Central Nervous System Tumors

**Session Type:** Oral Abstract Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 3:00 PM - 6:00 PM

- Central Nervous System Tumors

*Myrna Rachel Rosenfeld, MD, PhD*

- Central Nervous System Tumors

*John Frederick De Groot, MD*

- #LBA2001-NOA-08 randomized phase III trial of 1 week on/1 week off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem).

*Wolfgang Wick*

- #LBA2002-Glioblastoma (GBM) in Elderly Patients: A Randomized Phase III Trial Comparing Survival in Patients Treated with 6-week Radiotherapy (RT) versus hypofractionated RT over 2 weeks versus Temozolomide single agent Chemotherapy (TMZ) for Glioblastoma (GBM) in the Elderly.

*Annika Malmstrom, Dr*

- Discussion

*Stuart Grossman, MD*

- #2003-Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: A large prospective phase II trial.

*Alba Ariela Brandes, MD*

- #2004-Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS).

*David Neal Franz*

- #2005-Phase II study of preirradiation chemotherapy for CNS germ cell malignancies: Long-term complications.

*Steven I Robinson*

- #2006-Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB).

*Patrick Y. Wen, MD*

- #LBA2007-A prospective, randomized, open label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma.

*Roger Stupp, MD*

- #2008-Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study.

*Timothy Cloughesy, MD*

- Discussion

*Alba Ariela Brandes, MD*

**Session Title:** #167: Highlights of the Day I including Clinical Trials Participation Awards

**Session Type:** Highlights of the Day

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

*Everett E. Vokes, MD*

- Clinical Trials Participation Awards

- Discussion: Lymphoma and Plasma Cell Disorders  
*Bruce D. Cheson, MD*
  - Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy  
*Alan B Sandler, MD*
  - Discussion: Patient and Survivor Care  
*Gretchen Genevieve Kimmick, MD*
  - Discussion: Melanoma/Skin Cancers  
*F. Stephen Hodi, MD*
- 

**Session Title:** #196: Central Nervous System Tumors

**Session Type:** General Poster Session

**Date:** Sunday, June 6

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

1A #2033-Predictive impact of *IDH1* or *IDH2* mutations on outcome and response to temozolomide in low-grade gliomas.

*Caroline Houillier*

1B #2034-Prognostic factors for glioblastoma (GBM) in individuals age 70 and older: A study of 446 patients from two tertiary centers.

*Jacob G Scott*

1C #2035-Prognostic and predictive markers in recurrent high-grade glioma (HGG): Results from the BR12 randomized trial.

*Michael Brada, MD*

1D #2036-Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).

*Antonio Marcilio Padula Omuro*

1E #2037-Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials.

*Yaacov Richard Lawrence*

1F #2038-Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).

*Alise Brickhouse*

1G #2039-Open-label, dose confirmation, and dosimetry study of interstitial <sup>131</sup>I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results.

*William R. Shapiro*

1H #2040-Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL).

*Patrick Glyn Morris*

2A #2041-Quality-of-life concordance between patients with malignant gliomas (MG) and their caregivers.

*Daniel Jacobs*

2B #2042-18F-FET-PET hypermetabolic brain lesions: A correlation study to MRI and histopathologic findings.

*Armin Muigg*

2C #2043-Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients.

*Julie Bartolomeo*

2D #2044-Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients.

*Jean-Francois Baurain*

2E #2045-Long-term survival from the initial trial of bevacizumab and irinotecan.

*Annick Desjardins*

2F #2046-Secondary hematologic malignancies associated with temozolomide (TMZ) in patients with glioma.

*Hiroyuki Momota*

2G #2047-Influence of vascular endothelial growth factor (VEGF) single nucleotide polymorphisms (SNPs) on prognosis of glioblastoma (GB) patients.

*Claude Linassier*

2H #2048-Radiotherapy with or without temozolomide in elderly glioblastoma patients: Treatment results and prognostic factors.

*Ahmet Dirier*

3A #2049-A mesenchymal/stem cell predictor of survival of patients with malignant gliomas.

*Erik P. Sulman, MD, PhD*

3B #2050-Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation in patients with GBM.

*Nicholas A. Butowski*

3C #2051-Use of functional protein pathway activation mapping in glioblastoma samples to differentiate long-term from short-term survivors along with pathway-driven molecular subgroups.

*Claudius Mueller*

3D #2052-Expression of endoglin CD105 and nestin to assess neoangiogenesis in peritumor tissue of glioblastoma.

*Gigliola Sica (1)*

3E #2053-MGMT promoter methylation and *IDH1* mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.

*Agnieszka Wozniak*

3F #2054-Pseudoprogression after treatment with the TGF-beta 2 inhibitor trabedersen in high-grade glioma patients.

*Ulrich Bogdahn*

3G #2055-Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.

*Sith Sathornsumetee*

3H #2056-Current status of phase III anti-EGF-receptor antibody (OSAG-101) for newly diagnosed glioblastoma.

*Manfred Westphal*

4A #2057-Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

*Tobias Walbert*

4B #2058-Whole-brain radiotherapy with concurrent fixed-dose daily temozolomide for brain metastases treatment: A randomized phase II trial.

*Carlos Gamboa-Vignolle, MD*

4C #2059-Use of bevacizumab to facilitate up-front chemoradiation in poor-risk patients with glioblastoma multiforme by improving neurologic function.

*Richard M. Green*

4D #2060-Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results.

*Katherine Peters*

4E #2061-Evaluation of three stratification systems predicting recurrence and prognosis in patients with brain metastases after tumor removal and whole-brain irradiation.

*Victor Lee*

4F #2062-Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond.

*Arnab Chakravarti*

4G #2063-Use of FLAIR MRI in determining glioblastoma response to cediranib.

*Elizabeth Robins Gerstner*

4H #2064-Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study.

*Michael Platten*

5A #2065-Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).

*Mustafa Khasraw*

5B #2066^--A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one to three brain metastases: Preliminary results.

*Steven Brem*

5C #2067-Levels of circulating endothelial cells in relapsing glioblastoma patients responding to bevacizumab.

*Marica Eoli*

5D #2068-A prospective trial on the efficacy of a multiparametric imaging biomarker for early identification of GBM patients resistant to first-line therapy.

*Craig J Galbán*

5E #2069-Phase I/IIa trial of autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

*Yoshihiro Muragaki*

5F #2070-Temozolomide and radiation therapy in elderly patients affected by glioblastomas: A pooled analyses of three prospectic phase II trials.

*Alba Fiorentino*

5G #2071-High-dose radiation therapy using photons and carbon ion radiotherapy in patients with atypical and anaplastic meningiomas: Relevance of neuropathologic classification and therapeutic impact of a boost using of carbon ion radiotherapy.

*Stephanie E. Combs*

5H #2072-Phase II trial of combined temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.

*Sumitra Ananda*

6A #2073-Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas.

*John Kirkpatrick*

6B #2074-Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study.

*Salvador Villa*

6C #2075-Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM).

*Kent C. Shih*

6D #2076-MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network.

*Joerg Christian Tonn*

6E #2077-Preoperative blood parameters as biomarkers for high-grade gliomas.

*Mark Rosenthal*

6F #2078-Longitudinal analysis of physiologic MRI parameters in patients with newly diagnosed glioblastoma multiforme to predict outcome.

*Yan LI*

6G #2079-Characterization of pseudoprogression in patients with glioblastoma: Is histology the gold standard?

*Isaac Melguizo*

6H #2080-Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study.

*Nooshin Hashemi Sadraei*

7A #2081-Accuracy of a modeling algorithm to optimize perfusion MRI detection of glioma recurrence.

*Leland S Hu*

7B #2082-Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme.

*Vamsidhar Velcheti*

7C #2083-Phase I/II study of vandetanib for patients with recurrent malignant gliomas.

*Katharine Anne Mcnicol*

7D #2084-Correlation of cognitive symptoms with cognitive performance among brain cancer patients after radiation therapy.

*Stephen R. Rapp*

7E #2085-A new gene expression-based diagnostic test to predict prognosis of gliomas for the support of histopathologic diagnosis.

*Kikuya Kato*

7F #2086-Circulating endothelial cells, microparticles, and markers of inflammation and coagulation in glioblastoma patients before and after protracted temozolomide and radiotherapy.

*Gaspar Reynes*

7G #2087-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).

*Alexandra Benouaich-Amiel*

8A #2089-CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma.

*Sridharan Gururangan*

8B #2090-Assessment of diffusion parameters in scans prior to progression in GBM patients following antiangiogenic therapy.

*Laleh Jalilian*

8C #2091-Study of quality of life in brain tumor patients treated with three-dimensional conformal radiotherapy.

*Vankamamidi Venkata Sampath, MBBS*

8D #2092-Using a prospective comprehensive database to define features that impact the outcome of patients with glioblastoma multiforme.

*Kathryn Maree Field*

8E #2093-Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and systemic vaccination with tumor-lysate loaded dendritic cells in the stringent syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma immunity.

*Pedro R. Lowenstein*

8F #2094-A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression.

*Warren P. Mason*

8G #2095-A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme.

*Kenneth F. Grossmann*

9A #2097-Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107).

*Surasak Phuphanich*

9B #2098-New therapeutic approach for brain tumors: Intranasal administration of Ras inhibitor perillyl alcohol.

*Clovis O Fonseca*

**Session Title:** #143: Plenary Session including Science of Oncology Award and Lecture

**Session Type:** Plenary Session

**Date:** Sunday, June 6

**Location:** N Hall B1

**Time:** 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture  
*Douglas W. Blayney, MD*
- Plenary Session including Science of Oncology Award and Lecture  
*Daniel F. Hayes, MD*
- Plenary Session including Science of Oncology Award and Lecture  
*Frank McCormick, PhD, FRS*
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.  
  
*Robert A Burger*
- Discussion  
*Elizabeth A. Eisenhauer, MD*
- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).  
*Elisabeth A. Quoix*
- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).  
*Yung-Jue Bang*
- Discussion  
*Martin J. Edelman, MD*
- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.  
  
*Steven O'Day, MD*
- Discussion: Ipilimumab: The light at the end of the tunnel?  
*Vernon K Sondak, MD*

**Session Title:** #94: Stem Cells in Neuro-oncology

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** S100b

**Time:** 4:45 PM - 6:00 PM

- Stem Cells in Neuro-Oncology: overview  
*Richard Gilbertson, MD, PhD*
- CNS Stem Cells as Therapeutic Targets  
*Charles D. Stiles, PhD*
- Using Stem Cells to Treat Brain Tumors  
*Evan Snyder, MD, PhD*

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award  
*Kim Allyson Margolin, MD*
- Highlights of the Day II including Partners in Progress Award  
*Douglas W. Blayney, MD*
- Partners in Progress Award Recipient  
*Ellen V. Sigal, PhD*
- Discussion: Genitourinary (Prostate) Cancer  
*Nicholas J. Vogelzang, MD*
- Discussion: Gastrointestinal (Colorectal) Cancer  
*Howard S. Hochster, MD*
- Discussion: Gynecologic Cancer  
*Claire F. Verschraegen, MD*
- Discussion: Myeloma  
*Jean L. Harousseau, MD*
- Discussion: Cancer Prevention/Epidemiology  
*Scott Michael Lippman, MD*

**Session Title:** #135: Nonglial and Heritable Central Nervous System Tumors

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 1:15 PM - 2:30 PM

- Adult Meningioma: The Evolving Role for Oncologists

*Marc C. Chamberlain, MD*

- Neurofibromatosis Type 2

*Patrick Y. Wen, MD*

- Adult Medulloblastoma

*Michael Prados, MD*

**Session Title:** #22: Caring for the Child with Brain Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 3:00 PM - 4:15 PM

- High Dose Chemotherapy for Malignant Brain Tumors- What have we learned in the past 2 decades and what does the future hold for this therapy

*Amar J. Gajjar, MD*

- Relapsed Pediatric CNS tumors in 2010 □strategies and new agents

*Stewart Goldman, MD*

- Understanding Late Effects of Irradiation and Measures to Reduce Dose to Normal Tissue

*Thomas E. Merchant, DO, PhD*

**Session Title:** #134: Neuro-oncology for Medical Oncologists

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 3:00 PM - 4:15 PM

- Neurology perspective

*Lisa Marie DeAngelis, MD*

**Session Title:** #169: Highlights of the Day III

**Session Type:** Highlights of the Day

**Date:** Tuesday, June 8

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day III  
*Kathy Miller, MD*
- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy  
*Kathy Miller, MD*
- Discussion: Lung Cancer - Metastatic  
*Charles M. Rudin, MD, PhD*
- Discussion: Sarcoma  
*Gary K. Schwartz, MD*
- Discussion: Gastrointestinal (Noncolorectal) Cancer  
*C. D. Blanke, MD*
- Discussion: Head and Neck Cancer  
*Everett E. Vokes, MD*

**Session Title:** #95: Supportive Care for Patients with Non-small Cell Lung Cancer

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E353

**Time:** 9:30 AM - 10:45 AM

- Management of dyspnea and pleural effusion in patients with lung cancer  
*David Feller-Kopman, MD*
- Ancillary therapy for bone mets in the age of bisphosphonates  
*Vera Hirsh, MD*
- Management of brain metastases in lung cancer patients.  
*Minesh P. Mehta, MD*